Human papillomavirus detection in pregnant women: A prospective matched cohort study

Journal of Women's Health

Volumn 21, Issue 12, 2012, Pages 1295-1301

  Schmeink, Channa E ^a   Melchers, Willem J G ^b   Hendriks, Johannes C M ^a   Quint, Wim G V ^c   Massuger, Leon Fag ^a   Bekkers, Ruud L M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Medical Microbiology ^*  (Netherlands)

^c DDL Diagnostic Laboratory   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; QUESTIONNAIRE; SCORING SYSTEM; UTERINE CERVIX CYTOLOGY; VIRAL CLEARANCE; VIRUS DETECTION; WART VIRUS;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CERVIX UTERI; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MASS SCREENING; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; PROPENSITY SCORE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84870773947     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2012.3502     Document Type: Article

References (38)

1. Yoshikawa H, Nagata C, Noda K, et al. Human papillomavirus infection and other risk factors for cervical intraepithelial neoplasia in Japan. Br J Cancer 1999;80:621-624.
2. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: Collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007; 120:885-891.
3. Castellsague X, Munoz N. Cofactors in human papillomavirus carcinogenesis - Role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; 20-28.
4. Bosch FX, de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007; 23:213-227.
5. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: Results from a population-based study in Costa Rica. Br J Cancer 2001;84: 1219-1226.
6. Hoyo C, Yarnall KS, Fortney J. Short birth intervals and uterine cervical cancer risk in Jamaican women. Int J Gynaecol Obstet 2007;98:56-57.
7. Munoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: The IARC multicentric case-control study. Lancet 2002;359:1093-1101.
8. Molano M, van den BA, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: A population-based, 5-year follow-up study. Am J Epidemiol 2003;158:486-494.
9. Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006;119: 1108-1124.
10. Vaccarella S, Herrero R, Dai M, et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006;15:2148-2153.
11. Cotton SC, Sharp L, Seth R, et al. Lifestyle and sociodemographic factors associated with high-risk HPV infection in UK women. Br J Cancer 2007;97:133-139.
12. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002;94: 1406-1414.
13. Castle PE, Walker JL, Schiffman M, Wheeler CM. Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer 2005;117:1007-1012.
14. Kruger-Kjaer S, van den Brule AJ, Svare EI, et al. Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women. Int J Cancer 1998;76:613-619.
15. Brabin L. Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression. AIDS Patient Care STDs 2002;16:211-221.
16. Chang-Claude J, Schneider A, Smith E, Blettner M, Wahrendorf J, Turek L. Longitudinal study of the effects of pregnancy and other factors on detection of HPV. Gynecol Oncol 1996;60:355-362.
17. Chan PK, Chang AR, Tam WH, Cheung JL, Cheng AF. Prevalence and genotype distribution of cervical human papillomavirus infection: Comparison between pregnant women and non-pregnant controls. J Med Virol 2002;67: 583-588.
18. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. High-risk human papillomavirus clearance in pregnant women: Trends for lower clearance during pregnancy with a catch-up postpartum. Br J Cancer 2002;87:75-80.
19. Hernandez-Giron C, Smith JS, Lorincz A, Lazcano E, Hernandez- Avila M, Salmeron J. High-risk human papillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico. Sex Transm Dis 2005;32:613-618.
20. Fife KH, Katz BP, Roush J, Handy VD, Brown DR, Hansell R. Cancer-associated human papillomavirus types are selectively increased in the cervix of women in the first trimester of pregnancy. Am J Obstet Gynecol 1996;174: 1487-1493.
21. Fife KH, Katz BP, Brizendine EJ, Brown DR. Cervical human papillomavirus deoxyribonucleic acid persists throughout pregnancy and decreases in the postpartum period. Am J Obstet Gynecol 1999;180:1110-1114.
22. Banura C, Franceschi S, van Doorn LJ, et al. Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Int J Cancer 2008;123:2180-187.
23. Lenselink CH, Melchers WJ, Quint WG, et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS ONE 2008;3: e3743.
24. Rosenbaum PR. The central role of the propensity score in observational studies for causal effects. Biometrika Trust 1983;70:41-55.
25. Pearl J. Causality: Models, reasoning, and inference. second, 2nd ed. London: Cambridge Univeristy Press, 2009.
26. Melchers WJ, Bakkers JM, Wang J, et al. Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up. Am J Pathol 1999;155:1473-1478.
27. van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J Clin Microbiol 2006;44: 3122-3129.
28. Smith EM, Johnson SR, Jiang D. et al. The association between pregnancy and human papilloma virus prevalence. Cancer Detect Prev 1991;15:397-402.
29. Kemp EA, Hakenewerth AM, Laurent SL, Gravitt PE, Stoerker J. Human papillomavirus prevalence in pregnancy. Obstet Gynecol 1992;79:649-656.
30. de Roda Husman AM, Walboomers JM, Hopman E, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: The agerelated pattern. J Med Virol 1995;46:97-102.
31. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: Relationship between analytical and clinical sensitivity. J Pathol 2003;201:1-6.
32. Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F. Are self-collected samples comparable to physician- collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007;105:530-535.
33. Ogilvie GS, Patrick DM, Schulzer M, et al. Diagnostic accuracy of self-collected vaginal specimens for human papillomavirus compared to clinician-collected human papillomavirus specimens: A meta-analysis. Sex Transm Infect 2005;81:207-212.
34. Lorenzato FR, Singer A, Ho L, et al. Human papillomavirus detection for cervical cancer prevention with polymerase chain reaction in self-collected samples. Am J Obstet Gynecol 2002;186:962-968.
35. Safaeian M, Kiddugavu M, Gravitt PE, et al. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. Sex Transm Dis 2007;34: 429-436.
36. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26 (Suppl 10):K29-K41.
37. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-1597.
38. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-520.